Last Price
0.29
Today's Change
+0.019 (7.01%)
Day's Change
0.257 - 0.34
Trading Volume
4,678,696
Market Cap
2 Million
Shares Outstanding
8 Million
Avg Volume
7,268,282
Avg Price (50 Days)
0.26
Avg Price (200 Days)
0.32
PE Ratio
-0.54
EPS
-0.54
Earnings Announcement
27-Sep-2024
Previous Close
0.27
Open
0.26
Day's Range
0.2571 - 0.3399
Year Range
0.121 - 2.08
Trading Volume
4,716,039
1 Day Change
7.05%
5 Day Change
5.38%
1 Month Change
96.74%
3 Month Change
20.98%
6 Month Change
-14.71%
Ytd Change
-25.64%
1 Year Change
-69.25%
3 Year Change
-99.43%
5 Year Change
-99.87%
10 Year Change
-99.85%
Max Change
-94.15%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.